Introduction
Despite the armamentarium of antihypertensive drugs at present available, hypertension refractory to therapy remains a problem. In particular, the blood pressure in many patients with chronic renal failure, despite multiple drug combinations, is difficult to control. With the introduction of captopril, an angiotensin l-angiotensin II converting enzyme inhibitor, control of blood pressure in patients with refractory hypertension may be possible. We report the use of this drug in 6 patients with hypertension and chronic renal failure, 3 patients with hypertension following renal transplantation and one patient with renal hypertension and congestive cardiac failure (Table 1) .
Case reports
Case 1: A 21-year-old man was admitted in March 1979 with uncontrollable hypertension resulting in hypertensive encephalopathy and fits. A diagnosis of nephrotic syndrome secondary to membranoproliferative glomerulonephritis was first made in July 1976. Over the next two years his nephrotic syndrome persisted and his blood pressure rose. In October 1978 he was commenced on steroids because of deterioration in renal function. In November 1978 he developed hypertensive fits associated with cerebral oedema. Attempts at controlling his blood pressure up until March 1979 included the use of the following drugs: propranolol, clonidine, hydralazine, labetalol, phenoxybenzamine and diuretics. Blood pressure on treatment (Table I) before commencing captopril was 230/130 mmHg; following treatment with captopril (50 mg twice daily) blood pressure fell to 110/70 mmHg and propranolol and clonidine were discontinued. Proteinuria before starting captopril was 10.3 g/24 hours and now measures 2.1 g/24 hours, and his serum creatinine has improved (Table I ). The latest blood pressure is 140/90 mmHg.
Case 2: A 13-year-old boy with atrial septal defect presented in February 1979 with nephrotic syndrome secondary to severe crescentic glomerulonephritis. In July 1979 he was admitted with fits secondary to cerebral oedema and at this time his blood pressure was 170/125 mmHg. In August 1979, in view of the failure of other antihypertensives to control his blood pressure (Table 1) , he was started on captopril and the dose slowly increased to 100 mg three times daily. His blood pressure fell to 150/95 mmHg, but despite this he required haemodialysis in .... ... September 1979. He died in October 1979 of heart failure secondary to a large left-to-right heart shunt from this atrial septal defect.
Case 3: A 57-year-old woman presented in September 1979 with blood pressure recordings varying from 240/140 to 240/165 mmHg despite treatment (Table I) . Hypertension was originally diagnosed in 1959 and two years later she developed angina. She had been admitted on several occasions over the subsequent years for control of her blood pressure: this had been unsuccessful despite treatment with a number of antihypertensives which included guanethidine, reserpine, bethanidine, hydralazine, debrisoquine, methyldopa and clonidine. Captopril was started and Figure I shows the resultant control. A beta-blocker was added to control her angina. There was initial deterioration in renal function which improved on continuing captopril (50 mg twice daily). After six months treatment, she developed nausea on increasing captopril, and it was withdrawn. Minoxidil was started but had to be discontinued because of side effects and she is at present on labetalol.
Case 4: A 46-year-old woman was admitted in February 1980 with a blood pressure of 210/130 mmHg despite treatment (Table I) . She had originally presented with hypertensive encephalopathy in August 1978 (blood pressure 260/170 mmHg): A renal biopsy in October 1978 showed severe hypertensive vascular disease and focal glomerulonephritis. She developed terminal renal failure and started haemodialysis. In September 1978 a cadaveric renal transplantation was performed; her own kidneys were left in situ. Following the transplantation her blood pressure was poorly controlled, with diastolic blood pressure recordings between 105 and 125 mmHg. In view of the poor control of her hypertension she was started on captopril and other therapy tailed off. As a consequence her blood pressure came under control (Table I) . She is also receiving prednisolone 7.5 mg/day and azathioprine 100 mg/day as immunosuppression.
Case 5: A 14-year-old girl presented in 1975 with haemolytic uraemic syndrome and was treated with peritoneal and subsequently haemodialysis until May 1979 when she received a cadaveric renal transplant. In February 1980 she was admitted complaining of frontal headaches and vomiting; her blood pressure rose to 240/180 mmHg. Despite treatment (Table I) her hypertension was poorly controlled and she was started on captopril. Her hypertension is well controlled at present on captopril (50 mg three times daily) alone (Table I ). In addition she is on cyclosporin A as immunosuppression. (Table 1) . He was started on captopril and the dose increased to 100 mg three times daily. In view of his poor renal function (serum creatinine 250 umol/l), higher doses of captopril were not deemed advisable and prazosin (2 mg three times daily) was added to his therapy. In spite of this, his blood pressure was still poorly controlled, although systolic blood pressures were generally below 190 mmHg and diastolic blood pressures averaged 115 mmHg. He was discharged home, but required readmission one week later when his serum potassium was found to be 7 mmol/l (Figure 2 ). For two days captopril was continued but, in view of persistent hyperkalaemia, despite treatment with low potassium diet, oral calcium resonium, and intravenous dextrose and insulin, captopril was discontinued; his serum potassium over three days fell to within normal limits. Treatment with minoxidil resulted in severe fluid retention and heart failure despite concurrent diuretics and had to be discontinued. Captopril has been recommenced (100 mg four times daily) and the latest blood pressure is 170/100 mmHg.
Case 7: A 42-year-old man presented with malignant hypertension (blood pressure 230/160 mmHg) and left ventricular failure in February 1980. A renal biopsy was consistent with malignant hypertension. He was commenced on haemodialysis; his blood pressure was poorly controlled on labetalol (Table 1 ). In May 1980 captopril was started and now his blood pressure (on captopril 25 mg three times daily) is 140/90 mmHg.
Case 8: A 60-year-old man presented in June 1978 with dizziness and was found to have a blood pressure of 230/140 mmHg, proteinuria and mild aortic incompetence. Renal biopsy showed sclerosing proliferative glomerulonephritis. Despite a variety of antihypertensive drugs (Table I ) his blood pressure was poorly controlled and in November 1979 captopril was started and the dose increased to 100mg four times daily. He complained ofageusia and the dose was reduced to 100 mg twice daily with resultant improvement in his taste. Blood pressure on captopril, atenolol, hydralazine and diuretic is 190/95 mmHg. Proteinuria has remained constant at 1.2 g/24 hours.
Case 9: A 55-year-old woman was admitted in January 1980 with a three-month history of dyspnoea, abdominal pain, fatigue and ankle swelling. On examination she was in severe congestive cardiac failure with a blood pressure 190/120 mmHg and grade three hypertensive retinopathy. An intravenous urogram showed a small non-functioning right kidney and a hypertrophied left kidney. Renal vein renin levels were high on both sides. Despite treatment her heart failure and blood pressure were difficult to control and captopril was started in March 1980. Her blood pressure improved (Table I ) and heart failure resolved. Since starting captopril proteinuria has decreased from 1.9 to 1.1 g/24 hours.
Case 10: A 60-year-old man with chronic renal failure (serum creatinine 1126 umol/l) was admitted with uncontrolled hypertension (blood pressure 230/110 mmHg), despite therapy (Table 1) . A diagnosis of accelerated hypertension had been made in December 1976. , Captopril was started and the dose increased until his blood pressure was controlled (50 mg four times daily). Twelve days after staring captopril dialysis was commenced and captopril was reduced (25 mg three times daily). His present blood pressure is 155/85 mmHg.
Discussion
Hypertension in patients with chronic renal failure is particularly important to control since vascular disease accounts for half the deaths occurring in patients on maintenance haemodialysis. In addition, hypertension occurs in over two-thirds of patients following renal transplantation (Starzl et al. 1970) . Bilateral nephrectomy occasionally has been necessary to control hypertension in chronic renal failure, but it is associated with a morbidity of 3.6% (Yarimizu et al. 1978) to 9% (CaIman et al. 1976 ). In addition, it imposes both fluid and dietary restrictions on the patient and results in a worsening of the anaemia of chronic renal failure. Two new antihypertensive drugs, minoxidil and captopril, have diminished the need for bilateral nephrectomyin those patients with refractory hypertension. Minoxidil, a potent vasodilator, has potentially serious side effects of fluid retention and aggravation of underlying ischaemic heart disease, and it may also produce hypertrichosis which may be unacceptable in women (Dargie et al. 1977 , Kosman 1980 . Nevertheless, it has proved effective in patients with chronic renal failure and severe hypertension (Marquez-Julio et al. 1977) . In several studies captopril has been shown to be an effective agent in the management of patients with essential and renovascular hypertension (Atlas et al. 1979 , Prins, Donker et al. 1979 . Moreover, control of blood pressure in those patients with hypertension previously refractory to multiple drugs therapies has been achieved (Atkinson et al. 1980 , White et al. 1980 . There have been a few reports of patients with chronic renal failure treated with captopril with resultant good control of blood pressure (Brunner et al. 1978) . Aurell et al. (1980) have reported the use of captopril in 60 patients with severe hypertension, including 10 dialysis patients, 14 with end-stage renal failure and 12 transplant patients. They found a good response to treatment with few side effects.
Undoubted benefits of treatment in our patients included good control of blood pressure with a reduction of the number of tablets and different drugs and the consequent abolition of their associated side effects. Captopril was well tolerated and so improved the quality oflife of Our patients. Despite this, two complications arose-ageusia and hyperkalaemia. The former side effect occured in one patient but was dose related. In addition, life-threatening hyperkalaemia occurred in one patient. Bravo & Tarazi (1979) did not notice any significant change in serum potassium in their patients treated with captopril, while Atlas et al. (1979) noticed a potassium retention and rise in serum potassium even in patients with creatinine clearances over 50 ml/min. These changes were most marked in those with high renin levels prior to starting treatment with captopril. The potassium retention was related to a fall in plasma aldosterone which occurred on treatment and was noted within four days ofstarting treatment. As in other patients previously reported (Collste et al. 1979 , Grossman et al. 1980 ) the rise in serum potassium in our patient was associated with a deterioration in renal function which was reversible. Similar changes were noted in case 3 and have been ascribed to normotensive renal ischaemia (Collste et al. 1979) . In one patient in whom hyperkalaemia occurred, no deterioration in renal function was observed (Warren & O'Connor 1980) . Despite reports of the nephrotic syndrome complicating captopril therapy (Prins, Hoorntje et al. 1979 ), proteinuria did not occur de novo nor increase in those patients on captopril: indeed in 2 patients (cases 1 and 9) proteinuria decreased. Takeda et al. (1980) report a marked decrease of proteinuria in a patient with renovascular hypertension treated with captopril and ascribe this improvement to the abolition by captopril of increased formation of angiotension 11, which has been known to produce proteinuria. It is difficult to separate in case 1 the individual role of captopril and steroid therapy in this patient's marked reduction in proteinuria. In addition, no patient has developed agranulocytosis, a recognized complication particularly occurring in those who are immunosuppressed (Elijovisch & Krakoff 1980) . Recently, captopril has been shown to be effective in the control of chronic heart failure refractory to therapy with digitalis glycosides and diuretics by causing a decrease in arterial blood pressure, heart rate, pulmonary wedge pressure and systemic vascular resistance, while increasing cardiac index (Davis et al. 1979 , Levine et al. 1979 . In two patients in our series, there was undoubted benefit ofcaptopril in the control of both hypertension and heart failure.
Captopril therefore offers a potent alternative to minoxidil in the control of hypertension refractory to other treatments. Its ease of control, simplicity of drug regimen and relatively few side effects may result in a marked improvement in the quality of life as the patients are freed from the disabling side effects of other multiple antihypertensive drugs.
